Publications by authors named "A Cordon"
Distal hypoperfusion ischemic syndrome (DHIS), also known as dialysis access steal syndrome (DASS), is a rare but significant complication in patients with end-stage renal disease (ESRD) undergoing hemodialysis through arteriovenous fistulas (AVFs). This case report presents a female patient in her 40s with a complex medical history, including peripheral arterial disease, coronary artery disease, and recurrent cellulitis affecting her right hand, who developed DHIS following the placement of a brachiobasilic AVF. Despite optimal medical management, the patient exhibited persistent ischemic symptoms, including hand coolness and necrosis, ultimately requiring surgical ligation of the AVF.
View Article and Find Full Text PDFArticle Synopsis
- Despite clinical guidelines recommending lower use of central venous catheters (CVC), the prevalence remains high among patients undergoing hemodialysis, leading researchers to explore whether this is due to unavoidable circumstances or factors that can be addressed.
- A study involving 637 chronic hemodialysis patients from various centers in Spain sought to identify modifiable factors influencing CVC use, comparing demographics, vascular access types, and reasons patients had for not using arteriovenous fistulas (AVF).
- Results showed that 40% of the patients utilized CVCs, with major reasons for CVC use including patient refusal for surgery (often due to fear) and having initiated hemodialysis with a CVC, indicating that
Background: Systemic lupus erythematosus (SLE) is a rare autoimmune disorder characterized by an unpredictable course of flares and remission with diverse manifestations. Lupus nephritis, one of the major disease manifestations of SLE for organ damage and mortality, is a key component of lupus classification criteria. Accurately identifying lupus nephritis in electronic health records (EHRs) would therefore benefit large cohort observational studies and clinical trials where characterization of the patient population is critical for recruitment, study design, and analysis.
View Article and Find Full Text PDFBackground: In the demyelinating disease multiple sclerosis (MS), chronic-active brain inflammation, remyelination failure and neurodegeneration remain major issues despite immunotherapy. While B cell depletion and blockade/sequestration of T and B cells potently reduces episodic relapses, they act peripherally to allow persistence of chronic-active brain inflammation and progressive neurological dysfunction. N-acetyglucosamine (GlcNAc) is a triple modulator of inflammation, myelination and neurodegeneration.
View Article and Find Full Text PDF